6th Annual Conference on Stem Cell and Regenerative Medicine

Computational biomedicine is the use of computer-based tools and approaches to simulate and model the human body in health and disease. Medicine is a new and quickly expanding subject that encompasses the entire spectrum of human biology, physiology, and illness. This involves genomes as well as the entire human body, epidemiology, and community health. Molecular medicine, simulation, modeling approaches, imaging techniques, and information technology are all part of computational biomedicine What is the need for computational biomedicine? Humans are unique, complex systems with a plethora of information to be explored, from a biological cell made up of hundreds of different chemicals that work together, to the billions of cells that make up our tissue  organs, and organ systems, to our society, which is made up of 6 billion unique interacting individuals. Such complex systems do not have identical and replaceable parts. Individuals have individual personalities that add value and c

This blog addresses the consequences of stem cell research and commercial developments in the context of the pharmaceutical market's current size and growth, both globally and by the most important national markets. The key technologies that support stem cells are evaluated, as well as the nature and structure of the stem cell business, with profiles of the main companies and recent merger and acquisition (M&A) activities. Sales predictions for the national markets and the primary therapeutic categories of the drugs involved are offered for the next five years. Stem cells are the first cells to form after an egg and sperm combine and the resulting zygote begins to divide. They are the forerunners of all the numerous types of cells that comprise the human body. They are distinguished by self-renewal, or the ability to divide indefinitely to produce ever-larger populations of stem cells as well as the ability to differentiate into any adult cell type when given the necessary

Forge Biologics and Labcorp have entered into a collaboration to accelerate gene therapy development and commercialization. Forge Biologics is a gene therapy-focused contract development and manufacturing organization, while Labcorp is a leading global life sciences company that provides diagnostic and drug development services. The collaboration aims to leverage Forge Biologics' expertise in adeno-associated virus (AAV) gene therapy development and Labcorp's capabilities in clinical trial management , biomarker analysis, and diagnostic testing to accelerate the development of gene therapies. As part of the collaboration, Labcorp will provide clinical trial testing and biomarker analysis services, while Forge Biologics will provide AAV gene therapy development and manufacturing services. The collaboration will initially focus on advancing Forge Biologics' gene therapy pipeline, including its lead product candidate, FBX-101, for the treatment of Krabbe disease . The com